Associated Papers
Immunogenicity and Immune Silence in Human Cancer.
Yarmarkovich M et al.
Frontiers in Immunology, 2020
32256484 (PubMed )
Supplement: Table_4.XLSX › TCGA_HLAs_and_mutations
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.
Polivkova V et al.
Plos One, 2016
BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W et al.
Experimental and Molecular Pathology, 2012
Select a paper to view details